Association of a Variant of CNR1 Gene Encoding Cannabinoid Receptor 1 With Gilles de la Tourette Syndrome

被引:13
|
作者
Szejko, Natalia [1 ,2 ]
Fichna, Jakub Piotr [3 ]
Safranow, Krzysztof [4 ]
Dziuba, Tomasz [1 ]
Zekanowski, Cezary [3 ]
Janik, Piotr [1 ]
机构
[1] Med Univ Warsaw, Dept Neurol, Warsaw, Poland
[2] Med Univ Warsaw, Dept Bioeth, Warsaw, Poland
[3] Polish Acad Sci, Mossakowski Med Res Ctr, Dept Neurodegenerat Disorders, Lab Neurogenet, Warsaw, Poland
[4] Pomeranian Med Univ, Dept Biochem & Med Chem, Szczecin, Poland
关键词
Gilles de la Tourette syndrome; endocannabinoids; association study; CNR1; gene; CB1cannabinoid receptor 1; DELTA(9)-TETRAHYDROCANNABINOL THC; ENDOCANNABINOID SYSTEM; POLYMORPHISMS; DISORDER; THERAPY; OBESITY; IMPULSIVITY; IMPACT; INDEX; RISK;
D O I
10.3389/fgene.2020.00125
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Background Gilles de la Tourette syndrome (GTS) is a neuropsychiatric disorder of unknown etiology, although a major role of genetic factors has been established. Cannabis-based medicines may alleviate GTS-associated tics and variants of CNR1 gene encoding central cannabinoid receptor (CB1) are believed to be a risk factor for the development of some neurodevelopmental diseases. Our aim was to test the association of selected CNR1 gene variants with GTS. Material and Methods The cohort of GTS cases comprised 262 unrelated patients aged 3-53 years (mean age: 18.3 +/- 9.1 years; 204 males (77.9%), 126 (48.1%) adults defined as >= 18 years). As a control group we enrolled 279 unrelated, ethnically and gender matched individuals with no diagnosed mental, neurological or general disorder, aged 13-54 years (mean age: 22.5 +/- 3.0 years; 200 males, (74.1%). Both study and control groups were selected from Polish population, which is ethnically homogenous subgroup of Caucasian population. Four single nucleotide polymorphisms (SNPs) in CNR1 were selected: rs2023239, rs2180619, rs806379, and rs1049353 based on minor allele frequency in general population >15%. These variants were genotyped using a real-time quantitative polymerase chain reaction system (TaqMan SNP genotyping assay). Results We found significant association of GTS clinical phenotype with rs2023239 variant. Minor allele C and CT+CC genotypes were found significantly more often in GTS patients compared to controls (17.4 vs 11.1%, p=0.003 and 32.8 vs 20.4%, p=0.001, respectively), and the difference remained significant after correction for multiple testing. C allele of rs2023239 polymorphism of the CNR1 gene was associated with the occurrence of tics. There were no statistically significant associations for rs806379, rs1049353 or rs2180619 variants. Conclusion Our findings suggest that C allele of rs2023239 polymorphism of the CNR1 gene is a risk factor of GTS in Polish population. The variant can be potentially associated with abnormal endocannabinoid transmission, which is suspected to be one of the causes of GTS.
引用
收藏
页数:9
相关论文
共 50 条
  • [1] Association study of Cannabinoid receptor 1 (CNR1) gene in tardive dyskinesia
    Tiwari, A. K.
    Zai, C. C.
    Likhodi, O.
    Voineskos, A. N.
    Meltzer, H. Y.
    Lieberman, J. A.
    Potkin, S. G.
    Remington, G.
    Mueller, D. J.
    Kennedy, J. L.
    PHARMACOGENOMICS JOURNAL, 2012, 12 (03) : 260 - 266
  • [2] Association of CNR1 gene and cannabinoid 1 receptor protein in the human brain
    Pak, Kyoungjune
    Kantonen, Tatu
    Pekkarinen, Laura
    Nuutila, Pirjo
    Nummenmaa, Lauri
    JOURNAL OF NEUROSCIENCE RESEARCH, 2023, 101 (03) : 327 - 337
  • [3] Association study of a cannabinoid receptor gene (CNR1) polymorphism and schizophrenia
    Tsai, SJ
    Wang, YC
    Hong, CJ
    PSYCHIATRIC GENETICS, 2000, 10 (03) : 149 - 151
  • [4] Association of SLITRK1 to Gilles de la Tourette Syndrome
    Miranda, Debora M.
    Wigg, Karen
    Kabia, E. Mameisia
    Feng, Yu
    Sandor, Paul
    Barr, Cathy L.
    AMERICAN JOURNAL OF MEDICAL GENETICS PART B-NEUROPSYCHIATRIC GENETICS, 2009, 150B (04) : 483 - 486
  • [5] Association Study of Two Cannabinoid Receptor Genes, CNR1 and CNR2, with Methamphetamine Dependence
    Okahisa, Y.
    Kodama, M.
    Takaki, M.
    Inada, T.
    Uchimura, N.
    Yamada, M.
    Iwata, N.
    Iyo, M.
    Sora, I.
    Ozaki, N.
    Ujike, H.
    CURRENT NEUROPHARMACOLOGY, 2011, 9 (01) : 183 - 189
  • [6] A variant on promoter of the cannabinoid receptor 1 gene (CNR1) moderates the effect of valence on working memory
    Fairfield, Beth
    Mammarella, Nicola
    Franzago, Marica
    Di Domenico, Alberto
    Stuppia, Liborio
    Gatta, Valentina
    MEMORY, 2018, 26 (02) : 260 - 268
  • [7] Role of genetic variation in the cannabinoid type 1 receptor gene (CNR1) in the pathophysiology of human obesity
    Schleinitz, Dorit
    Carmienke, Solveig
    Bottcher, Yvonne
    Toenjes, Anke
    Berndt, Janin
    Kloeting, Nora
    Enigk, Beate
    Mueller, Ines
    Dietrich, Kerstin
    Breitfeld, Jana
    Scholz, Gerhard H.
    Engeli, Stefan
    Stumvoll, Michael
    Blueher, Matthias
    Kovacs, Peter
    PHARMACOGENOMICS, 2010, 11 (05) : 693 - 702
  • [8] A frequent polymorphism in the coding exon of the human cannabinoid receptor (CNR1) gene
    Gadzicki, D
    Müller-Vahl, K
    Stuhrmann, M
    MOLECULAR AND CELLULAR PROBES, 1999, 13 (04) : 321 - 323
  • [9] CNR1, central cannabinoid receptor gene, associated with susceptibility to hebephrenic schizophrenia
    Ujike, H
    Takaki, M
    Nakata, K
    Tanaka, Y
    Takeda, T
    Kodama, M
    Fujiwara, Y
    Sakai, A
    Kuroda, S
    MOLECULAR PSYCHIATRY, 2002, 7 (05) : 515 - 518
  • [10] The cannabinoid receptor 1 gene (CNR1) and multiple sclerosis: an association study in two case-control groups from Spain
    Ramil, E.
    Sanchez, A. J.
    Gonzalez-Perez, P.
    Rodriguez-Antiguedad, A.
    Gomez-Lozano, N.
    Ortiz, P.
    Arroyo, R.
    De las Heras, V.
    Vilches, C.
    Garcia-Merino, A.
    MULTIPLE SCLEROSIS JOURNAL, 2010, 16 (02) : 139 - 146